Cytosorbents (NASDAQ:CTSO) Now Covered by StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a note issued to investors on Monday. The firm set a “hold” rating on the medical research company’s stock.

A number of other analysts have also issued reports on the stock. HC Wainwright restated a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a research report on Monday, November 11th. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Cytosorbents in a research report on Friday, January 3rd. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Trading Down 3.3 %

Cytosorbents stock opened at $0.94 on Monday. The stock has a 50-day moving average price of $0.92 and a 200 day moving average price of $1.03. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.59. The stock has a market cap of $51.27 million, a PE ratio of -2.60 and a beta of 0.58. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06.

Institutional Investors Weigh In On Cytosorbents

Institutional investors have recently added to or reduced their stakes in the company. Sargent Investment Group LLC lifted its stake in shares of Cytosorbents by 4.9% in the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after purchasing an additional 67,181 shares in the last quarter. Atomi Financial Group Inc. acquired a new stake in shares of Cytosorbents in the third quarter valued at about $51,000. Finally, Geode Capital Management LLC raised its holdings in shares of Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after buying an additional 32,415 shares during the period. Hedge funds and other institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.